Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 78Prostatic Neoplasms, Castration-Resistant 3Neoplasm Metastasis 3Prostatic Diseases 2Neoplasms 2Genital Diseases, Male 2Urogenital Neoplasms 1Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Patient Preference 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Low Risk Prostate Cancer 1High-Risk and Oligometastatic Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Neoplasms, Male 1Castration Levels of Testosterone 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × apalutamide × Clear all
NCT04295447 2024-06-20

ADAM

Universität Münster

Phase 2 Active not recruiting
190 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT02578797 2023-11-09

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Aragon Pharmaceuticals, Inc.

Phase 1 Completed
45 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡